EBF recommendation on practical management of critical reagents for PK ligand-binding assays

被引:14
|
作者
Pihl, Susanne [1 ]
van der Strate, Barry W. A. [2 ]
Golob, Michaela [3 ]
Vermet, Laurent [4 ]
Jaitner, Birgit [5 ]
Goodman, Joanne [6 ]
Fjording, Marianne Scheel [7 ]
Timmerman, Philip [8 ]
机构
[1] Ascendis Pharma AS, Copenhagen, Denmark
[2] PRA Hlth Sci, Assen, Netherlands
[3] Nuvisan GmbH, Grafing, Germany
[4] Sanofi Res & Dev, Montpellier, France
[5] Novartis Pharma AG, Basel, Switzerland
[6] MedImmune, Cambridge, England
[7] Novo Nordisk AS, Malov, Denmark
[8] European Bioanal Forum, Havenlaan 86c b204, B-1000 Brussels, Belgium
关键词
antibodies; critical reagents; ligand-binding assays; major change; minor change; PK assay; ANALYTE STABILITY; BIOANALYSIS; VALIDATION;
D O I
10.4155/bio-2018-0230
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Critical reagents play a crucial role in ligand-binding assays; the robustness and reliability of an assay is defined by the quality and long-term availability of these reagents. However, neither regulatory guidelines nor relevant scientific papers provide clear directions for set-up, life cycle management and, more importantly, the acceptance criteria required for the testing of the critical reagents for pharmacokinetic, biomarker and immunogenicity assays. The ambiguity from current guidelines can be a challenge for the bioanalytical community. Members of the European Bioanalysis Forum community undertook a more pragmatic approach on how to assess the impact of critical reagents. In this paper, a review and corresponding gap analysis of the current guidelines and relevant papers will be provided as well as decision trees proposed for lot-to-lot changes of critical reagents for pharmacokinetic assays.
引用
收藏
页码:1557 / 1566
页数:10
相关论文
共 50 条
  • [41] DIRECTLY MEASURED SIGNALS AS RESPONSE VARIABLES IN FLUORESCENCE POLARIZATION LIGAND-BINDING ASSAYS
    HALFMAN, CJ
    WONG, FCL
    SCHNEIDER, AS
    [J]. ANALYTICAL CHEMISTRY, 1984, 56 (09) : 1648 - 1650
  • [42] Practical aspects of the ligand-binding and enzymatic properties of human serum albumin
    Kragh-Hansen, U
    Chuang, VTG
    Otagiri, M
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2002, 25 (06) : 695 - 704
  • [43] Specificity and Accuracy Data for Ligand-binding Assays for Macromolecules Should be Interpreted with Caution
    Findlay, John W. A.
    [J]. AAPS JOURNAL, 2008, 10 (03): : 433 - 434
  • [44] Singlicate analysis: should this be the default for biomarker measurements using ligand-binding assays?
    Ye, Zhuqiu
    Tu, Jing
    Midde, Krishna
    Edwards, Mike
    Bennett, Patrick
    [J]. BIOANALYSIS, 2018, 10 (12) : 909 - 912
  • [45] Specificity and Accuracy Data for Ligand-binding Assays for Macromolecules Should be Interpreted with Caution
    John W. A. Findlay
    [J]. The AAPS Journal, 10
  • [46] Time-resolved fluorescence ligand-binding assays for parathyroid hormone receptors
    Emami-Nemini, A.
    Roux, T.
    Leblay, M.
    Bourrier, E.
    Lamarque, L.
    Trinquet, E.
    Lohse, M. J.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2012, 385 : 24 - 24
  • [47] UTILITY OF PHOTOAFFINITY LABELS AS REAGENTS FOR IDENTIFICATION OF LIGAND-BINDING PROTEINS AT CONCENTRATIONS BELOW NANOMOLAR
    KNOTT, JCA
    RAJEWSKY, K
    [J]. ZEITSCHRIFT FUR IMMUNITATSFORSCHUNG-IMMUNOBIOLOGY, 1977, 153 (04): : 321 - 322
  • [48] Are matrix effects the Achilles heel in the bioana-lysis of biotherapeutics by ligand-binding assays?
    Wang, Qingqing
    Ma, Mark
    [J]. BIOANALYSIS, 2014, 6 (08) : 1041 - 1044
  • [49] Selectivity of ligand-binding assays in relationship to the measurement of biologics: how much does it matter?
    Hill, Howard
    [J]. BIOANALYSIS, 2010, 2 (09) : 1525 - 1530
  • [50] Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules
    Binodh DeSilva
    Wendell Smith
    Russell Weiner
    Marian Kelley
    JoMarie Smolec
    Ben Lee
    Masood Khan
    Richard Tacey
    Howard Hill
    Abbie Celniker
    [J]. Pharmaceutical Research, 2003, 20 : 1885 - 1900